Position in ROIV
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$1,419,139
+$865,139 QoQ
Shares Held
40,100
+100.5% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#216
of 494 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capricorn Fund Managers Ltd holds $71,636,795 across 13 Biotechnology names. ROIV ranks #10 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
321,721 | $18,276,970 | |
| 2 | ZYME |
Zymeworks Inc.
|
486,529 | $12,717,868 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
101,240 | $11,852,166 | |
| 4 | MLTX |
MoonLake Immunotherapeutics
|
374,866 | $7,298,641 | |
| 5 | CYTK |
Cytokinetics Inc
|
81,879 | $6,975,272 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
63,900 | $5,212,323 | |
| 7 | PVLA |
Palvella Therapeutics, Inc.
|
14,088 | $2,152,928 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
41,300 | $1,598,310 |
All Filings in ROIV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,419,139 | 40,100 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $554,000 | 20,000 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $9,667,350 | 445,500 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $3,003,305 | 198,500 | Shares | Sole | 2025-10-17 | |
| No filing history on record for this holder in this stock. | ||||||